Context: The Government of India (GOI) has announced the third stimulus package of Rs. 900 Crore for the Mission COVID Suraksha- The Indian COVID-19 Vaccine Development Mission. 
Key Points

• This grant will be provided to the Department of Biotechnology (DBT) for Research & Development of Indian COVID-19 vaccines.
• The COVID-19 Vaccine development Mission with end-to-end focus from preclinical development through clinical development and manufacturing and regulatory facilitation for deployment, would consolidate all available and funded resources towards an accelerated product development. 
• This will help accelerate development of approx. 5-6 vaccine candidates and ensure that these are brought closer to licensure and introduction in market for consideration of regulatory authorities for introduction in public health systems, to combat further spread of COVID infection.

The important objectives of the fund will be 

• accelerating pre-clinical & clinical development; 
• licensure of COVID-19 vaccine candidates that are currently in clinical stages or ready to enter clinical stage of development, establishing clinical trial sites, and 
• strengthening the existing immunoassay laboratories, central laboratories and suitable facilities for animal studies, production facilities and other testing facilities to support COVID-19 vaccine development. 
• supporting development of common harmonized protocols, trainings, data management systems, regulatory submissions, internal and external quality management systems and accreditations.   

Capabilities for process development, cell line development and manufacturing of GMP batches for animal toxicology studies and clinical trials will also be supported under the Mission. A key element will be development of suitable Target Product Profile so that vaccines being introduced through the mission have preferred characteristics applicable for India.

• Phase-I of the COVID Suraksha Mission has been allotted Rs.900 Crore for a period of 12 months.
• A total of 10 vaccine candidates have been supported by Department of Biotechnology so far at both academia and industry and as on date, 5 vaccine candidates are in human trials including the Russian Vaccine Sputnik-V with at least 3 more in advanced stages of preclinical to enter human trials shortly. 

Significance

• Mission COVID Suraksha is the targeted effort to enable development of indigenous, affordable and accessible vaccines for India and will complement the National Mission of Atmanirbhar Bharat.
• India has exhibited enormous strength in vaccine manufacturing and India’s vaccine manufacturers will develop affordable and accessible vaccine not only for India but the World.